VBI in Novel mRNA-Launched eVLP Vaccine Program

 

• Preclinical data suggests novel mRNA-launched eVLPs (“MLE”) generate significantly enhanced B-cell and T-cell responses compared to mRNA-expression of antigens alone
• In addition to immunologic benefits, new MLE technology enables manufacturing of particulate vaccines on an accelerated timeline, similar to other mRNA manufacturing timelines
• Based on encouraging data seen to date, MLE proprietary technology is under evaluation by multiple potential partners, including by both pharmaceutical and biotechnology companies
• Detailed preclinical data are also being targeted for presentation at a future scientific conference

https://www.biospace.com/article/releases/vbi-vaccines-expands-proprietary-technology-platforms-with-development-of-a-novel-mrna-launched-evlp-vaccine-program/